Orient Europharma Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Taipei Taiwan (1982)
Status: No NME R&D (1982)

Organization Overview

First Clinical Trial
2009
NCT00910741
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Orient Europharma Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 2)

Asthma (Phase 4)

Carcinoma (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Head and Neck Neoplasms (Phase 1)

Hypercholesterolemia (Phase 3)

Hypotension (Phase 2)

Liver Diseases (Phase 4)

Osteoarthritis (Phase 1)

Osteoarthritis, Knee (Phase 1)

Pancreatic Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial APIs: 16